- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05904951
The INVADER™ Percutaneous Transluminal Coronary Angioplasty (PTCA) Post Market Clinical Follow-up (PMCF) Study
June 13, 2023 updated by: Alvimedica
Balloon Dilatation Catheter for the Dilation of Stenotic Atherosclerotic Lesions in Coronary Artery or Bypass Grafts: Evaluation of Safety and Performance in Everyday Clinical Practice. The INVADER™ Percutaneous Transluminal Coronary Angioplasty (PTCA) Post Market Clinical Follow-up (PMCF) Study
The aim of the present observational study is to collect clinical data on the non-implantable medical device INVADER™ PTCA in the daily use in an unselected population.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey
- Alvimedica
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study population consisted of all consecutive patients treated with the INVADER™ PTCA at the study sites: all patients who met the inclusion/exclusion criteria were enrolled
Description
Inclusion Criteria:
- To be a Turkish citizen,
- To be >18 years of age,
- Lesion must be successfully crossed with a guidewire without complication,
- INVADER™ PTCA is used in the primary lesion treated during the procedure,
- Patient has signed and dated the informed consent.
Exclusion Criteria:
- Patients who have a known allergic reaction to any of the composition of INVADER™ PTCA Balloon Dilatation Catheter.
- Device use not consistent with Instructions for Use (IFU).
- Patients concurrently participating in another medical device or pharmaceutical clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device success
Time Frame: 48 hours after index procedure
|
Measurement: Percentage of lesions among all attempted lesions with:
|
48 hours after index procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of individual components of device success
Time Frame: 48 hours after index procedure
|
48 hours after index procedure
|
|
Procedural success:
Time Frame: 48 hours after index procedure
|
o Measurement: Percentage of device success without major adverse cardiovascular events (MACE) (composite of all death, myocardial infarction [MI], and clinically indicated target lesion revascularization [CI-TLR]).
|
48 hours after index procedure
|
Rate of Target Lesion Failure (TLF)
Time Frame: 48 hours after index procedure
|
o Measurement: Percentage of a composite of cardiac death, target vessel myocardial infarction (TV-MI), and CI-TLR.
|
48 hours after index procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2022
Primary Completion (Actual)
April 30, 2023
Study Completion (Actual)
April 30, 2023
Study Registration Dates
First Submitted
May 30, 2023
First Submitted That Met QC Criteria
June 13, 2023
First Posted (Actual)
June 15, 2023
Study Record Updates
Last Update Posted (Actual)
June 15, 2023
Last Update Submitted That Met QC Criteria
June 13, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C32104
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Diseases
-
Terumo Europe N.V.CompletedPeripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular ProcedureBelgium, France, Germany
-
University Hospital, MontpellierTerminated
-
Alvotech Swiss AGActive, not recruitingChorioretinal Vascular DiseaseGeorgia
-
AmgenCompletedChorioretinal Vascular DiseaseUnited States
-
Duke UniversityTerminatedRetinal Vascular DiseaseUnited States
-
University of California, IrvineUniversity of Oklahoma; US Department of Veterans Affairs; C. R. Bard; Long Beach...CompletedPeripheral Vascular Disease | Cardiac Catheterization | Vascular Access ComplicationsUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Regeneron PharmaceuticalsCompletedChorioretinal Vascular DiseaseUnited States
-
Terumo Europe N.V.Terumo Medical CorporationRecruitingPeripheral Vascular Disease | Hemostasis | Vascular Closure | Femoral Artery | Endovascular ProcedureFrance, Germany, Netherlands
Clinical Trials on INVADER™ PTCA Balloon Dilatation Catheter
-
Boston Scientific CorporationCompletedCoronary Artery DiseaseUnited States
-
Zhejiang Zylox Medical Device Co., Ltd.CompletedPeripheral Arterial Disease | Popliteal Artery Stenosis | Popliteal Artery Occlusion | Iliac Artery Occlusion | Femoral Artery Occlusion | Iliac Artery Stenosis | Femoral Artery Stenosis
-
Advanced NanoTherapiesMonash University; Cardiovascular Research Foundation, New York; Cogent Technologies...Recruiting
-
BrosMed Medical Co., LtdCompleted
-
CCRF Inc., Beijing, ChinaShanghai 10th People's HospitalNot yet recruitingCoronary Artery Disease
-
Suzhou Zhonghui Medical Technology Co., Ltd.RecruitingPeripheral Arterial DiseaseChina
-
BrosMed Medical Co., LtdCompletedCoronary Artery DiseaseChina
-
NexStep MedicalNot yet recruiting
-
Sino Medical Sciences Technology Inc.Peking University First HospitalCompletedCoronary Stenosis | Coronary Artery Stenosis | In-stent RestenosisChina
-
NexStep MedicalRecruitingVascular DiseasesFrance